Intended audience: This website is intended for healthcare professionals, institutions and business partners. It is not directed at patients or the general public and does not constitute medical advice or consumer-directed promotion of a medical device.

Investigational device notice: EVEA™ is an investigational medical device under development. It is not approved, cleared, or available for sale in any jurisdiction. Clinical information on this site reflects published literature on intravaginal culture as a method — not EVEA™-specific data.

A lower-infrastructure approach to embryo culture

EVEA™ is designed to reduce the specialised laboratory infrastructure and embryology resources typically required for conventional IVF.

Request a briefing →

Illustration for reference only. Actual device may differ.

In underserved markets, the embryology lab is a major barrier to IVF access

Every conventional IVF cycle requires specialised laboratory space, incubator capacity and embryology expertise. Where that infrastructure does not exist, patients travel — or go untreated.

Demand

1 in 6

people affected by infertility worldwide — a WHO-recognised disease.

(WHO, 2023)

Constraint

$500K–$1M+

illustrative capital benchmark to build a conventional embryology cleanroom — varies by country, facility and scope.

(Market benchmarks; Eve estimate)

Operational difference

~59%

fewer embryology-lab hours per cycle — Eve operational model, not clinical-trial data.

(Eve cycle modelling)

Method history

35+ yrs

of published intravaginal-culture clinical literature — the method, not EVEA™-device data.

(Published IVC literature)

Three areas where EVEA™ is designed to require less

The Embryology Lab

Reduced infrastructure requirement

Lower cleanroom-grade scope than a conventional IVF lab.

The Incubator Bank

Reduced

Lower reliance on open-dish culture infrastructure.

Specialist Hours

Reduced

Lower hands-on embryology time under Eve's model.

*Eve operational modelling based on Eve's current cycle model. Not clinical-trial data, and not a validated workforce study. To be confirmed with partners and validated against site-specific conditions.

Culture still requires a qualified laboratory, quality systems and regulatory compliance.

Evaluate EVEA™ for your institution.

For hospital systems, fertility operators, investors, regulators and partners across Asia-Pacific.

Request a briefing → Explore EVEA™